Novartis psoriasis drug superior to Enbrel in study

July 8, 2013 12:57 PM

12 0

Novartis psoriasis drug superior to Enbrel in study

ZURICH (Reuters) - Novartis psoriasis drug secukinumab was superior to Amgen's Enbrel in a late-stage study, the Swiss company said on Monday, putting it in line to become the first of a clutch of new treatments to gain market approval.

A phase III trial involving 1,307 patients showed that secukinumab was more effective than Enbrel in clearing skin in patients with moderate to severe plaque-type psoriasis, a painful and unsightly skin condition that causes itching and scaling.

Read more

To category page

Loading...